Track topics on Twitter Track topics that are important to you
Pfizer revealed in its briefing on its second quarter financials that Ibrance, its breast cancer treatment, had grown in sales by 66% but overall revenue was down to $12.9 billion from $13.15 billion.
The company revealed that the primary reason for this drop off in sales was due to the generic erosion of its essential health segment, which sells older, off-patent drugs. In this area, sales dropped by 14% to $5.23 billion.
Original Article: Pfizer’s major drug doubles sales but overall revenue fallsNEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...